Your session is about to expire
← Back to Search
Extracorporeal Support
Intraoperative ECMO Strategies for Lung Transplant
N/A
Waitlist Available
Led By Basil Nasir, MD
Research Sponsored by Centre hospitalier de l'Université de Montréal (CHUM)
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up beginning from the arrival to the intensive care unit immediately after surgery, up to about 30 days
Awards & highlights
No Placebo-Only Group
Summary
This trial is testing whether using a specific medical support only when needed during lung transplants is as effective as using it routinely. The study focuses on patients without severe heart or lung issues to see if this approach reduces complications. Recent improvements in technology have led to better outcomes in lung transplantation.
Who is the study for?
This trial is for patients undergoing lung transplant surgery within a 6-month period. It's not suitable for those who can't consent, are having multiple organ transplants, or must have intraoperative support due to severe pulmonary hypertension, significant heart dysfunction, or retransplantation.
What is being tested?
The study compares two approaches during lung transplant surgery: 'Routine ECMO' where all patients receive cardiopulmonary support and 'On demand ECMO' where support is provided only if serious heart or oxygen issues arise during the operation.
What are the potential side effects?
Potential side effects may include complications from using the ECMO machine such as bleeding, blood clots, infection risk increase and possible damage to organs like kidneys or brain due to reduced blood flow.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ beginning from the arrival to the intensive care unit immediately after surgery, up to about 30 days
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~beginning from the arrival to the intensive care unit immediately after surgery, up to about 30 days
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Other study objectives
Duration of mechanical ventilation in hours
Perioperative blood product transfusion requirements
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
2Treatment groups
Experimental Treatment
Active Control
Group I: On demand ECMO (study group)Experimental Treatment1 Intervention
Group II: Routine ECMO (control group)Active Control1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
On demand ECMO
2022
N/A
~30
Research Highlights
Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
Extracorporeal Membrane Oxygenation (ECMO) is a critical treatment for managing severe postoperative complications by providing cardiopulmonary support. ECMO works by oxygenating the blood outside the body and removing carbon dioxide, which helps maintain hemodynamic stability and adequate oxygenation in patients with compromised lung function or severe pulmonary hypertension.
This is particularly important in postoperative patients who may experience severe hypoxia or hemodynamic instability, as ECMO can bridge the gap when traditional methods are insufficient, thereby improving patient outcomes and reducing the risk of severe complications.
Find a Location
Who is running the clinical trial?
Centre hospitalier de l'Université de Montréal (CHUM)Lead Sponsor
377 Previous Clinical Trials
131,492 Total Patients Enrolled
3 Trials studying Postoperative Complications
1,017 Patients Enrolled for Postoperative Complications
Basil Nasir, MDPrincipal InvestigatorCentre hospitalier de l'Université de Montréal (CHUM)
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- I have had an organ transplant before.I am scheduled for a lung transplant within the next 6 months.I need support during my lung transplant surgery as doing it without support is unsafe.I have severe pulmonary hypertension.I cannot or do not want to give consent for this study.I have had a transplant involving multiple organs.I have had surgery or stenting for severe heart artery blockages.
Research Study Groups:
This trial has the following groups:- Group 1: On demand ECMO (study group)
- Group 2: Routine ECMO (control group)
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.